BACTERIAL RESISTANCE MARKERS IN SEPSIS OF NEWBORN IN ZLITEN MEDICAL CENTER
Main Article Content
Keywords
.
Abstract
Background A lot of newborn patients with sepsis need antibiotic treatment, but some antibiotics are ineffective and cause bacteria to develop resistance markers (a gene that produces a protein that makes cells that express this protein resistant to antibiotics). Choosing antibiotics wisely can lower the mortality rate and promote the prudent use of antibiotics.
Aim We analyze the pattern of antibiotic use and the sensitivity patterns of antibiotics to support the rational use of antibiotics in neonate patients with sepsis.
Material and method Total sample of 211 blood sample were collected from neonate showing with clinical signs of sepsis at Zletin Medical Center during January-December 2022 year 2022 was Staphylococcus epidermidis, and the most antibiotic-resistant bacteria was Acinetobacter. The sample was then cultivated, and resistance markers assessed using Phoenix BD CPO.
Result The sample were divided into no bacterial growth and bacterial growth. we found that 165 sample (78.19%) have not bacterial growth and 44 samples (20.85%) have bacterial growth Staphylococcus epidermidis (20.45%), Klebsiella pneumonia (9.09%), Staphylococcus hemolyticus (11.36%), Acinatobacter baumanii/calcoaceticus complex (2.36%), Pseudomonas putida (2.72%), Klebsilla oxytoca (2.72%), Echereshia coli (2.72%), Staphylococcus aureus (2.72%).
Conclusion Based on the results of the trials, the most bacteria causing sepsis in the neonatal department at Zliten Medical Center during the year 2022 was Staphylococcus epidermidis, and the most antibiotic-resistant bacteria was Acinetobacter.
References
2. Simonsen KA, Anderson-Berry AL, Delair SF, Davies HD. Early-onset neonatal sepsis. Clin Microbiol Rev. 2014 Jan;27(1):21-47.
3. Seale AC, Blencowe H, Manu AA, Nair H, Bahl R, Qazi SA, Zaidi AK, Berkley JA, Cousens SN, Lawn JE., pSBI Investigator Group. Estimates of possible severe bacterial infection in neonates in sub-Saharan Africa, south Asia, and Latin America for 2012: a systematic review and meta-analysis. Lancet Infect Dis. 2014 Aug;14(8):731-741.
4. Simonsen KA, Anderson-Berry AL, Delair SF, Davies HD. Early-onset neonatal sepsis. Clin Microbiol Rev. 2014 Jan;27(13):21-47.
5. Shane AL, Stoll BJ. Recent developments and current issues in epidemiology, diagnosis, and management of bacterial and fungal neonatal sepsis. Am J Perinatol. 2013 Feb;30(2):131-41.
6. Weston EJ, Pondo T, Lewis MM, Martell-Cleary P, Morin C, Jewell B, Daily P, Apostol M, Petit S, Farley M, Lynfield R, Reingold A, Hansen NI, Stoll BJ, Shane AL, Zell E, Schrag SJ. The burden of invasive early-onset neonatal sepsis in the United States, 2005-2008. Pediatr Infect Dis J. 2011 Nov;30(11):937-41.
7. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence,outcome, and associated costs of care. Crit Care Med 2001, 29: (13)03-1310.
8. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D: Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006, (34): 344-353.
9. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N: Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006, 355: 1018-1028.
10. Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA: The sepsis seesaw: tilting toward immunosuppression. Nat Med 2009, (15): 496-497.
11. Limaye AP, Kirby KA, Rubenfeld GD, Leisenring WM, Bulger EM, Neff MJ, Gibran NS, Huang ML, Santo Hayes TK, Corey L, Boeckh M: Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008, (300): 413-422.
12 Luyt CE, Combes A, Deback C, Aubriot-Lorton MH, Nieszkowska A, Trouillet JL, Capron F, Agut H, Gibert C, Chastre J: Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation. Am J Respir Crit Care Med 2007,(175): 935-942.
12. Tetta C, Bellomo R, Inguaggiato P, Wratten ML, Ronco C: Endotoxin and cytokine removal in sepsis. Ther Apher 2002,(6): 109-115.
13. Deans KJ, Haley M, Natanson C, Eichacker PQ, Minneci PC: Novel therapies for sepsis: a review. J Trauma 2005, (58): 867-874.
14. Ronco C, Tetta C, Mariano F, Wratten ML, Bonello M, Bordoni V, Cardona X, Inguaggiato P, Pilotto L, d'Intini V, Bellomo R: Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs 2003, (27): 792-801.
15. Honoré PM, Matson JR: Extracorporeal removal for sepsis: acting at the tissue level--the beginning of a new era for this treatment modality in septic shock. Crit Care Med 2004, 32: 896-897.
16. Di Carlo JV, Alexander SR: Hemofiltration for cytokine-driven illnesses: the mediator delivery hypothesis. Int J Artif Organs 2005, 28: 777-786.
17. Peng Z, Singbartl K, Simon P, Rimmele T, Bishop J, Clermont G, Kellum JA: Blood purification in sepsis: a new paradigm. Contrib Nephrol 2010, (165): 322-328.
18. Croatto, A.,et al.,Evalutaion of the BD Phoenix CPO Detect Test for the cabapenemase produc Clinical microbiology and Infection 2020.26(5),p.644.e15.
19. Mahapatra, aghosh , s. k. ; mishra , s. ; pattnaik , d. ; pattnaik,k.andmohanty,s.k.. “enterobacter cloaca:apredominant pathogen in neonatal septicemia . indian” journal of meaical microbiology. 20 ( 2 ) : issn 2002. 0255 – 0857.
20. Gales , A. C. ; Pignatari , A.C. Jones , R.N. ; Baretta , M. and Sader , H.S. “Evaluation of vitro activity of new fluoroquinolones , cephalosporins and carbapenems against 569 gram negative bacteria” .. Rev. Assoc. Med. Bras. 43(2) : 1997. 137-144.
21. Sabio Paz, D.V. , Solana , C. ; Trietsch , R. and O, Donnell , Y.A..” Influenza A: una causa poco frecuente de neumonia end periodo neonatal precoz “. Arch. Argent. Pediatr . 2001. 99 (1): 55-57 .
21. Stephan, j; Korn und pramod, M. And Shah Frankfurt, M. " In vitro activity of linezolid against staphylococcus spp. Compared to other antibiotics.' Chemother 2002. (11); 87-9 .
22. Kaufhola, a. and Klein, R.. 'species identification and antibiotic susceptibility of enterococcus isolated from clinical specimens of hospitalized patients '.Zentrabl. Bakteriot. 282 (3); 1995. 507-518.
23. Croatto, A.,et al.,Evalutaion of the BD Phoenix CPO Detect Test for the cabapenemase produc Clinical microbiology and Infection 2020.26(5),p.644.e15.
24. Ratanarat R, Brendolan A, Piccinni P, Dan M, Salvatori G, Ricci Z, Ronco C: Pulse high-volume haemofiltration for treatment of severe sepsis: effects on hemodynamics and survival. Crit Care 2005,(9): R294-302.
25. Joannes-Boyau O, Honoré PM, Boer W, Collin V: Are the synergistic effects of high-volume haemofiltration and enhanced adsorption the missing key in sepsis modulation? Nephrol Dial Transplant 2009, (24): 354-357.
26. Rimmele T, Assadi A, Cattenoz M, Desebbe O, Lambert C, Boselli E, Goudable J, Etienne J, Chassard D, Bricca G, Allaouchiche B: High-volume haemofiltration with a new haemofiltration membrane having enhanced adsorption properties in septic pigs. Nephrol Dial Transplant 2009, (24): 421-427.
27. Joannes-Boyau O, Honoré PM, Boer W, Collin V: Are the synergistic effects of high-volume haemofiltration and enhanced adsorption the missing key in sepsis modulation? Nephrol Dial Transplant 2009, (24): 354-357.
28. Uchino S, Bellomo R, Goldsmith D, Davenport P, Cole L, Baldwin I, Panagiotopoulos S, Tipping P: Super high flux hemofiltration: a new technique for cytokine removal. Intensive Care Med 2002, (28): 651-655.
29. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, (29): 1303-1310.
30. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D: Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006, (34): 344-353.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Ibrahim. Abdallah
Lecturer, Pharmaceutical Chemistry Department, Pharmacy College, Al Asmarya Islamic University
Fatema Edmesho
Pharm, Pharmaceutical Chemistry Department, pharmacy College, Al Asmarya Islamic University
Ayada abuhdemah
Lecturer, Pharmaceutical Chemistry Department, Pharmacy College, Al Asmarya Islamic University
Ryad Alati
Lecturer, pharmacology and Toxicology Department , Pharmacy College, Al Asmarya Islamic University